Cost effectiveness analysis comparing repetitive transcranial magnetic stimulation to antidepressant medications after a first treatment failure for major depressive disorder in newly diagnosed patients - A lifetime analysis.
Jeffrey D VoigtLinda CarpenterAndrew LeuchterPublished in: PloS one (2017)
rTMS was identified as the dominant therapy compared to antidepressant medication trials over the life of the patient across the lifespan of adults with MDD, given current costs of treatment. These models support the use of rTMS after a single failed antidepressant medication trial versus further attempts at medication treatment in adults with MDD.
Keyphrases
- major depressive disorder
- transcranial magnetic stimulation
- newly diagnosed
- bipolar disorder
- high frequency
- healthcare
- end stage renal disease
- randomized controlled trial
- chronic kidney disease
- stem cells
- peritoneal dialysis
- bone marrow
- adverse drug
- mesenchymal stem cells
- study protocol
- smoking cessation
- drug induced